knowledge -WSS

knowledge

author：knowledge 2025-09-07 17:30:47 - browse：78

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company.

Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday. The partners announced the new company, yet unnamed, earlier this week, but the release was light on detail. The strategic partnership will house Elevance and CD&R’s doctors, clinics, and the technologies that help those doctors manage their patients.

Health insurers specialize in managing medical costs, and through ventures like this, they apply that expertise to managing patients’ chronic medical conditions. In arrangements like Medicare Advantage, where insurers are paid set amounts for members’ care, they’re incentivized to keep those patients healthy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Change Healthcare outage fallout shows need for new oversight

entertainment

WSS

FDA's Woodcock to retire early next year

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Congress must reauthorize a committee to support older Americans

Wegovy, Zepbound and weight loss drugs that preserve muscle

World's first CRISPR

In key trial, Verve's treatment lowers cholesterol levels in patients

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

explore

Duchenne breakthrough therapy leaves behind pioneering families

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Wildfire smoke exposes gaps in outdoor worker protections

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

What does generative AI mean for health care? We asked experts

World's first CRISPR

Dobbs anniversary: the lost opportunity of abortion as health care

Ebola: Gilead Sciences antiviral shows promise as new treatment

The cancer drug shortage isn’t new — and neither are the solutions

As AI in medicine takes off, can 'human in the loop' prevent harm?

explore

Why scientists need input from humanists on sensitive research

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Why medical students are struggling with mental health

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

As AI in medicine takes off, can 'human in the loop' prevent harm?

leisure time

entertainment

knowledge

knowledge